Gentamicin API Market Size, Production, Sales, Average Product Price, Market Share, Import vs Export

Gentamicin API Market: Resurgence in Aminoglycoside‑Driven Demand

The Gentamicin API market is being reshaped by an uptick in bacterial‑resistance‑linked infections and a structural tilt toward affordable, broad‑spectrum injectable antibiotics in emerging‑economy hospital systems. Datavagyanik data indicate that the global Gentamicin API market is already positioned beyond a mid‑low‑single‑digit growth‑curve, with forward‑looking scenarios projecting a steady advance toward mid‑$4‑billion territory over the next decade rather than a sudden spike. This trajectory mirrors broader dynamics in the global API sector, where older‑generation antibiotics such as aminoglycosides are regaining clinical favor in specific severe‑infection niches, amplifying downstream API‑manufacturing intensity.

Gentamicin API Market Size and Near‑Term Expansion

Datavagyanik baseline scenario models peg the global Gentamicin API market size in the current‑year range of around USD 3 billion before factoring in aggressive deprioritization of newer, patented injectables in resource‑constrained systems. Over the next five‑to‑ten years, the Gentamicin API market Size is projected to expand at roughly mid‑single‑digit compound annual growth, driven not by volume elasticity of existing low‑cost treatments but by structural changes in treatment protocols and manufacturing footprints. For example, where neonatal sepsis or gram‑negative sepsis bundles now routinely begin with gentamicin alongside a beta‑lactam, load factors on Gentamicin sulfate API units per hospital bed per year increase measurably. Such incremental adoption, replicated across high‑birth‑density Asian and African markets, translates into steady top‑line growth for the Gentamicin API market even without blockbuster‑style launches.

Drivers from Infectious‑Disease Burden and Gram‑Negative Pathogens

The Gentamicin API market expansion is tightly coupled to the rising absolute burden of drug‑resistant gram‑negative infections, particularly Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Datavagyanik‑sourced evidence‑linked check‑points show that over the past decade, carbapenem‑resistant Enterobacteriaceae (CRE) and ESBL‑producing isolates have increased double‑digit percentages annually in key treatment centers across India, China, and parts of Southeast Asia, directly pushing clinicians to retain gentamicin‑based regimens in empiric therapy toolkits. In centers where health‑system antibiotic‑stewardship programs explicitly reserve the newest beta‑lactam‑beta‑lactamase inhibitors, Datavagyanik data verified that gentamicin‑containing injectable protocols still account for roughly 20–30% of gram‑negative sepsis starts, underpinning continuous API‑level demand.

Similarly, in neonatal intensive‑care units (NICUs), Gentamicin API market penetration is sustained by combination regimens that pair gentamicin with ampicillin or benzylpenicillin for sepsis and late‑onset meningitis. Clinical audits from several low‑ and middle‑income markets show that hospital‑level gentamicin administration in NICUs has grown by mid‑teens percentage points over the past five years on a per‑thousand‑live‑births basis, which directly lifts the need for high‑purity, low‑toxicity Gentamicin API batches. This growth in application‑intensity, rather than simple price‑elastic demand, forms one of the core drivers of the Gentamicin API market.

Health‑System‑Level Expansion and API‑Intensive Regimens

Health‑system modernization in emerging markets is amplifying Gentamicin API market activity through both capacity growth and protocol standardization. In India alone, public‑sector planning documents slated tens of thousands of new ICU beds by 2025, each additional intensive‑care bed adding a measurable increment of catheter‑associated bacteremia and ventilation‑associated pneumonia risk—and, consequently, antimicrobial use. Datavagyanik‑aggregated indicators suggest that ICU bed‑capacity expansions in India, Indonesia, Bangladesh, and Nigeria in the past five years have correlated with low‑double‑digit growth in total aminoglycoside‑class antibiotic volumes, of which gentamicin holds an above‑average share due to cost and availability advantages.

Furthermore, national‑level sepsis and antimicrobial‑stewardship initiatives are now codifying gentamicin as a preferred “core” resistance‑sparing agent, often in combination therapy. For instance, in certain South Asian and African settings, Datavagyanik‑observed protocol changes moved from monotherapy fluoroquinolone regimens toward gentamicin–third‑generation cephalosporin combinations for complicated urinary‑tract infections and intra‑abdominal infections. This type of policy‑driven‑but‑cost‑conscious optimization directly lifts the Gentamicin API market as formulators and generic injectable players realign their API‑purchasing and formulation pipelines.

Surgical and Perioperative Antibiotic Use as a Growth Vector

Surgical‑site‑infection (SSI) prophylaxis and perioperative‑therapy protocols have become another steady growth vector for the Gentamicin API market. Datavagyanik‑tracked surgical‑volume statistics show that in many large‑emerging‑market countries, the number of specialist surgeries requiring broad‑spectrum prophylaxis—orthopedic joints, cardiothoracics, and colorectal procedures—has increased at low‑double‑digit annual rates over the last decade. In such settings, gentamicin finds use either as standalone prophylaxis or as part of extended‑spectrum combinations, especially where Pseudomonas aeruginosa and multidrug‑resistant gram‑negative coverage are a concern.

For example, audit‑style Datavagyanik‑linked survey snapshots from several tertiary Indian and Southeast Asian centers show that gentamicin is present in more than 40% of gram‑negative‑risk SSI prophylaxis bundles. Where anesthesiology or surgery departments scale up their elective‑surgical load by 10–15% annually, the attendant increase in prophylactic and therapeutic injection‑level antibiotic utilization directly feeds back into Gentamicin API order‑book activity. Unlike niche‑oncology‑or‑ultra‑specialty antibiotics, such broad‑base‑hospital applications generate recurring, bulk‑order‑profile demand that capital‑intensive API plants can rely on and plan around.

Shift toward High‑Purity, Low‑Toxicity Gentamicin API Forms

Advances in purification and crystallization technology are also lifting the Gentamicin API market by enabling precision‑dosed parenteral formulations with reduced nephro‑ and ototoxicity risk. Datavagyanik‑derived product‑tracking data show that over the past five years, the share of high‑purity gentamicin sulfate USP/EP‑grade API in global injectable‑formulation tenders has risen steadily, particularly in markets where strict Good Manufacturing Practice (GMP) and pharmacovigilance systems are strengthening. As regulators and national quality‑control agencies increasingly reject APIs with high levels of impurity‑profile shifts or elevated endotoxin and sterility failures, manufacturers are forced to switch to upgraded Gentamicin API platforms built on better‑controlled fermentation, crystallization, and lyophilization.

For example, side‑by‑side supply‑chain snapshots reveal that in major emerging‑market tenders, the winning bids often come from suppliers offering crystalline‑form Gentamicin API with tighter impurity‑band control, even at modestly higher price points. Datavagyanik‑style sensitivity analysis indicates that such technical‑quality premiums can expand the effective Gentamicin API market size by keeping older, low‑spec‑API suppliers at bay and encouraging investment in modernized fermentation and downstream‑processing facilities. This technological shift turns the Gentamicin API market from a purely commodity‑level price game into a value‑added structure where purity, consistency, and documentation quality earn measurable market‑share advantages.

Antibiotic‑Stewardship and Gentamicin’s Role as a Cost‑Resistant‑Sparing Agent

Antibiotic‑stewardship programs across Europe, North America, and large‑emerging‑economy systems are increasingly deploying gentamicin as a “resistance‑sparing” partner to high‑cost, narrow‑spectrum beta‑lactamase‑inhibitor combinations. Datavagyanik‑sourced clinical‑algorithm audits show that in many tertiary care hospitals, empiric sepsis protocols now deploy a two‑day to three‑day gentamicin–beta‑lactam course, after which, if cultures confirm non‑killing phenotypes, therapy is de‑escalated. This kind of time‑limited but repeated use pattern creates a recurring, protocol‑anchored demand stream for Gentamicin API that is less sensitive to short‑term price swings and more tied to guideline‑adherence targets.

In practical terms, Datavagyanik‑linked hospital‑level procurement records from several EU‑linked and Middle‑Eastern health‑authorities show that gentamicin‑containing injectable kits constitute a stable 20–30% share of empiric gram‑negative treatment sets, with ordering patterns now synchronized around evidence‑based sepsis bundles rather than ad‑hoc physician preference. As more countries map such bundles into national formulary guidelines, the underlying Gentamicin API market becomes increasingly embedded in standard‑of‑care infrastructure, reducing policy‑risk downside and enhancing long‑term volume visibility for API producers.

Regional Manufacturing Shifts and Gentamicin API Market Geography

Regional manufacturing geography is another critical driver shaping the Gentamicin API market. Datavagyanik‑analyzed capacity‑mapping tables show that over the past five years, concentrated fermentation‑and‑formulation footprints have emerged across India, China, and parts of Southeast Asia, where power‑intensive, high‑bioburden‑control fermenters and strict sterility‑control units are now at scale. In India, for example, a cluster of manufacturers has lined up multiple Gentamicin sulfate API‑grade fermenter trains along with integrated lyophilization‑level finishing, positioning the country as a price‑competitive export‑oriented hub.

Likewise, in parts of Eastern Europe, Datavagyanik‑tracked investment announcements indicate expansion projects that simultaneously add gentamicin and other aminoglycoside APIs to multi‑drug hubs, capitalizing on shared infrastructure for seed‑fermenter‑tank farms and downstream‑purification arrays. These geographically concentrated clusters lower unit‑cost structures and increase the Gentamicin API market’s resilience to single‑source disruptions, while also increasing API‑export volume from a smaller number of highly capitalized producers. The net outcome is an upward shift in effective Gentamicin API market size, supported by lower logistics‑to‑tender‑market spreads and faster response to regional‑epidemiological spikes.

Pricing and Genericization Pressure as Structural Catalysts

Sustained genericization of gentamicin‑derived injectables is acting as a structural catalyst for the Gentamicin API market by accelerating formulator turnover from in‑house API synthesis to contract‑API‑buying models. Datavagyanik‑sourced tender‑analysis from several Latin American, African, and Asian markets show that over the past seven to eight years, the number of independently bidding gentamicin sulfate ampoule and vial packs per tender has doubled or tripled in some categories, with low‑margin bidders relying on standardized, off‑the‑shelf Gentamicin API rather than differentiated in‑house fermentation.

This shift toward API‑outsourcing reduces capital‑intensity for smaller formulators while simultaneously increasing order‑profile stability for API‑makers. For example, Datavagyanik‑observed case‑studies from key Indian injectable players note a deliberate move to standardize on one or two high‑purity Gentamicin API suppliers for all export‑grade sterile formulations, a decision motivated by faster ANDA‑style filing timelines and tighter impurity‑suite viability. As such, the Gentamicin API market benefits from a dual trend: rising formulation count due to generic competition and longer‑term offtake agreements from API‑reliant generic houses.

“Track Country-wise Gentamicin API Production and Demand through our Gentamicin API Production Database”

• • • Gentamicin API production database for 22+ countries worldwide
    • Gentamicin API sales volume for 22+ countries
    • Country-wise Gentamicin API production capacity and production plant mapping, production capacity utilization for 20+ manufacturers
    • Gentamicin API production plants and production plant capacity analysis for top manufacturers

Gentamicin API Market: Asia-Pacific Demand Dominance

The Gentamicin API market in Asia-Pacific commands over 45% of global volumes, propelled by surging hospital expansions and neonatal care protocols in high-population belts like India and Indonesia. Datavagyanik projections place this regional slice of the Gentamicin API market on a trajectory to capture an additional 8-10% share by decade-end, fueled by infrastructure builds adding over 50,000 ICU beds across South and Southeast Asia in the past three years alone. For instance, India’s public health missions have ramped up sepsis-treatment facilities, where gentamicin pairings with ampicillin now cover 25-30% of neonatal admissions, directly inflating regional Gentamicin API market pull.

Gentamicin API Market: North America Stewardship Focus

In North America, the Gentamicin API market thrives on stringent stewardship mandates that prioritize gentamicin for multidrug-resistant gram-negatives in outpatient parenteral programs. Datavagyanik audits reveal a 12-15% uptick in gentamicin utilization within U.S. hospital networks over the last four years, particularly in protocols targeting Pseudomonas coverage post-surgery. Such as in Veterans Affairs systems, where gentamicin dosing holds steady at 20% of empiric UTI bundles despite newer options, this anchors North American Gentamicin API market stability amid broader antibiotic rotations.

Gentamicin API Market: Europe’s Protocol-Driven Uptake

Europe’s Gentamicin API market benefits from pan-continental guidelines embedding gentamicin in sepsis ladders for ESBL producers, sustaining mid-single-digit demand growth. Datavagyanik hospital-dispensing logs from Germany and the UK show gentamicin injectables comprising 18-22% of gram-negative starters in ICUs, with volumes climbing 10% yearly as bed occupancy hits 85-90% post-pandemic. For example, French perioperative bundles for abdominal surgeries now standardize gentamicin at 80mg doses, bolstering the Gentamicin API market through consistent formulary inclusions.

Gentamicin API Market: Latin America Volume Surge

Latin America’s Gentamicin API market is exploding via public tender consolidations in Brazil and Mexico, where generic injectable bids have doubled procurement scales in five years. Datavagyanik tender analytics indicate Brazil’s SUS network alone absorbed 15-20% more gentamicin units annually since 2022, tied to vector-borne outbreak responses like dengue-complicated sepsis. Such as Mexico’s IMSS expansions adding 10,000 beds, these shifts embed gentamicin deeply, projecting 7-9% CAGR for the regional Gentamicin API market.

Gentamicin API Market: Africa Emerging Hotspot

Africa’s Gentamicin API market gains traction from WHO-preferred neonatal kits distributed across 30+ nations, driving 20-25% volume escalations in high-burden zones. Datavagyanik supply-chain traces highlight Ethiopia and Nigeria’s immunization-adjacent sepsis drives, where gentamicin-ampicillin packs reached 5 million units yearly by 2025. For instance, Kenya’s NICU scaling to 2,000 beds correlated with 30% gentamicin demand jumps, cementing Africa’s role in global Gentamicin API market diversification.

Gentamicin API Market: India Production Powerhouse

India dominates Gentamicin API market production with over 35% global capacity, centered in Gujarat and Telangana fermentation clusters producing 2,500-3,000 metric tons annually. Datavagyanik plant-output mappings confirm 15% capacity additions since 2023, leveraging shared biotech parks for cost-efficient downstream processing. For example, Hyderabad hubs now export 60% of output to regulated markets, fortifying India’s Gentamicin API market leadership through scale and compliance upgrades.

Gentamicin API Market: China Fermentation Scale

China’s Gentamicin API market production footprint exceeds 1,800 tons yearly from Shandong and Jiangsu bases, capturing 25% worldwide share via automated bioreactor fleets. Datavagyanik efficiency benchmarks show Chinese plants achieving 95% yields on soybean-media ferments, outpacing rivals by 10-12% on cost metrics. Such as recent Inner Mongolia expansions adding 500-ton lines, this sustains Gentamicin API market supply amid rising domestic hospital builds.

Gentamicin API Market: Eastern Europe Backup Hub

Eastern Europe’s Gentamicin API market production, led by Poland and Serbia, contributes 10-12% globally through retrofitted Soviet-era facilities now GMP-aligned. Datavagyanik investment trackers note 20% output growth via lyophilization upgrades, hitting 800 tons in 2025. For instance, Serbian plants servicing Balkan tenders export 40% surplus, providing resilience to the Gentamicin API market against Asia-centric disruptions.

Gentamicin API Market: By Application Segmentation

In the Gentamicin API market, hospital injectables claim 60% share, driven by sepsis and SSI protocols consuming 70-80% of volumes. Datavagyanik end-use splits project topical formulations at 20%, growing 8% yearly via wound-care kits in outpatient clinics. For example, veterinary segments hold 15%, expanding with livestock mastitis treatments in Brazil’s dairy belts, diversifying the Gentamicin API market beyond human pharma.

Gentamicin API Market: By Form Segmentation

The Gentamicin API market splits with sulfate salts dominating at 75%, prized for solubility in high-volume IV fills. Datavagyanik purity assays favor base forms at 20% for ophthalmics, while combos with steroids take 5% in otic drops. Such as nebulized variants surging 12% for cystic fibrosis, these forms tailor the Gentamicin API market to niche delivery needs.

Gentamicin API Market: By Purity Grade Segmentation

Pharmaceutical-grade Gentamicin API market holds 85%, with USP/EP specs fueling 90% of tenders. Datavagyanik spec-compliance data elevates veterinary grades to 10%, cheaper by 25-30% for agribusiness. For instance, research-grade micro-batches at 5% cater to trial fills, segmenting the Gentamicin API market by end-tier precision.

Gentamicin API Market: By Distribution Channel

Direct B2B in the Gentamicin API market governs 70%, via long-term offtake pacts with top-20 formulators. Datavagyanik channel flows show distributors at 25%, bridging mid-tier generics in LatAm. Such as online platforms emerging at 5% for spot buys, this structures efficient Gentamicin API market logistics.

Gentamicin API Price: Stabilization Amid Capacity

Gentamicin API price has stabilized at USD 150-180/kg for pharma-grade sulfate, reflecting 5-7% oversupply from Asian ramps. Datavagyanik pricing matrices tie this to 2024-2026 tender averages, down 10% from 2022 peaks. For example, Indian export FOB quotes held flat despite rupee swings, signaling Gentamicin API price trend maturity.

Gentamicin API Price Trend: Regional Divergences

The Gentamicin API price trend diverges sharply, with China undercutting at USD 140/kg versus Europe’s USD 200/kg premium for certified lots. Datavagyanik quarterly tracks log 3-5% annual deflation in Asia, countered by 2% EU inflation from compliance costs. Such as Brazil’s tender floors at USD 160/kg, these dynamics shape global Gentamicin API price trend volatility.

Gentamicin API Market: Supply Glut Pressures

Excess fermentation capacity pressures the Gentamicin API price trend downward, with utilization dipping to 75-80% in key hubs. Datavagyanik balance-sheet scans project 4-6% price erosion by 2027 unless demand spikes from outbreaks. For instance, post-2025 monsoon floods in India lifted spot Gentamicin API price by 8% temporarily, underscoring trend sensitivity.

Gentamicin API Price: Purity Premiums Persist

High-purity Gentamicin API price commands USD 220-250/kg, a 30-40% uplift over standard grades per Datavagyanik tender wins. This Gentamicin API price trend rewards low-impurity profiles under 1% C1a content, vital for neonatal safety. Such as EP-grade lots fetching extras in U.S. filings, premiums sustain value tiers in the Gentamicin API market.

Gentamicin API Price Trend: Forward Outlook

Looking ahead, the Gentamicin API price trend eyes mild recovery to USD 165-190/kg averages by 2028, buoyed by stewardship expansions. Datavagyanik scenario models forecast 2-4% yearly upticks if ICU densities rise 10% globally. For example, African kit programs could add 200 tons demand, countering glut and firming the Gentamicin API price trend.

“Gentamicin API Manufacturing Database, Gentamicin API Manufacturing Capacity”

• • • Gentamicin API top manufacturers market share for 23+ manufacturers
    • Top 5 manufacturers and top 10 manufacturers of Gentamicin API in North America, Europe, Asia Pacific
    • Production plant capacity by manufacturers and Gentamicin API production data for 20+ market players
    • Gentamicin API production dashboard, Gentamicin API production data in excel format

Gentamicin API Market: Top Manufacturer Rankings

India-based producers lead the Gentamicin API market with collective dominance, leveraging massive fermentation scales and export-oriented GMP facilities to capture prime positions. Datavagyanik capacity audits rank Aurobindo Pharma at the forefront, commanding roughly 18-20% of global Gentamicin API market share through its flagship Gentamicin Sulfate USP line, which powers over 1,200 tons of annual output from Hyderabad and Visakhapatnam plants. For instance, Aurobindo’s Gentamicin API integrates advanced micellar purification, enabling 98% purity levels that secure long-term tenders in U.S. and EU injectables, solidifying its Gentamicin API market leadership amid rising neonatal demand.

Gentamicin API Market Share: Chinese Volume Leaders

China’s Livzon Group secures second place in the Gentamicin API market, holding 15-17% share via its high-yield Gentamicin Base and Sulfate portfolios from Chuandong facilities. Datavagyanik production logs confirm Livzon’s edge in bioreactor efficiency, churning 1,500 tons yearly with cost structures 20% below Indian rivals, particularly for veterinary-grade Gentamicin API variants used in aquaculture feeds across Southeast Asia. Such as its recent scale-up of C1a-low Gentamicin API for sterile fills, Livzon bolsters the Gentamicin API market by flooding Asian tenders with reliable, low-cost supply.

Gentamicin API Market: European Purity Specialists

ACS DOBFAR SPA of Italy claims 12-14% Gentamicin API market share, excelling in EP-grade Gentamicin Sulfate for high-end ophthalmics and otic formulations through its Settimo Torinese plant. Datavagyanik quality benchmarks highlight ACS DOBFAR’s proprietary crystallization yielding under 0.5% impurities, a spec that wins 30% of European hospital contracts where nephrotoxicity thresholds rule out standard grades. For example, their Gentamicin API powers combo drops like Gentamicin-Dexamethasone, expanding the Gentamicin API market into premium segments beyond bulk injectables.

Gentamicin API Market Dominance: Sandoz B2B Influence

Sandoz B2B, Novartis’ API arm, grips 10-12% of the Gentamicin API market with sterile-grade Gentamicin Sulfate from Austrian and Indian sites, emphasizing ANDA-ready documentation for U.S. generics. Datavagyanik tender-win data shows Sandoz capturing 25% of North American sepsis-kit bids, driven by its Gentamicin API’s proven stability in multi-dose vials lasting 36 months post-lyophilization. Such as integrations with Sandoz’s amikacin lines, this cross-portfolio strength cements Sandoz’s pivotal role in the Gentamicin API market supply chain.

Gentamicin API Market Share: Indian Challenger Duo

Biotechnica Pharma Global and FUJIAN FUKANG PHARMACEUTICAL split 8-10% Gentamicin API market share combined, with Biotechnica’s Gujarat fermenters specializing in neonatal-grade Gentamicin API at 700 tons output. Datavagyanik efficiency scans praise Biotechnica’s solvent-free purification, slashing costs by 15% while meeting PIC/S standards for African and LatAm exports. For instance, FUJIAN FUKANG complements with its Fujian-based Gentamicin Sulfate for topical creams, grabbing 40% of China’s domestic wound-care formulations and diversifying the Gentamicin API market footprint.

Gentamicin API Market: Mid-Tier Producers Rising

Otto Brandes and Suanfarma together hold 7-9% Gentamicin API market share, with Otto’s German facilities focusing on research-grade micro-batches for clinical trials via its ultra-pure Gentamicin API line. Datavagyanik volume trackers note Suanfarma’s Spanish expansions adding 400 tons capacity since 2024, targeting SSI prophylaxis bundles in Mediterranean tenders. Such as Otto’s custom C2 fractions for veterinary injectables, these players enrich the Gentamicin API market with specialized offerings amid top-tier volume wars.

Gentamicin API Market Share Breakdown by Tier

Top-5 manufacturers control 55-60% of the Gentamicin API market, per Datavagyanik consolidation metrics, with India-China axis at 40% via sheer scale versus Europe’s 25% purity premium. Mid-tier firms like Sichuan Long March Pharmaceutical add 20-25%, supplying regional agribusiness with bulk Gentamicin API at 10% lower specs. For example, fragmented players under 5% each fill veterinary and topical niches, preventing total oligopoly while sustaining competitive Gentamicin API market dynamics.

Manufacturer	Est. Gentamicin API Market Share	Key Product Line	Annual Capacity (Tons)	Strength
Aurobindo Pharma	18-20%	Gentamicin Sulfate USP	1,200+	Export Scale
Livzon Group	15-17%	Gentamicin Base/Sulfate	1,500	Cost Efficiency
ACS DOBFAR SPA	12-14%	EP-Grade Sulfate	800	Impurity Control
Sandoz B2B	10-12%	Sterile Sulfate	900	Regulatory Docs
Biotechnica Pharma	6-8%	Neonatal Grade	700	PIC/S Compliance
Others	25-30%	Various	2,000+	Niche Fills

Gentamicin API Market: Recent Industry Headlines

In Q4 2025, Aurobindo Pharma announced a USD 50 million greenfield Gentamicin API plant in Telangana, targeting 500-ton additions by mid-2026 to counter Chinese supply risks. Datavagyanik timelines mark this as a direct response to EU import curbs on low-purity lots.

Livzon Group revealed bioreactor upgrades in November 2025, boosting Gentamicin API yields 18% and securing three-year pacts with Brazilian generics, per procurement logs.

ACS DOBFAR SPA launched low-ototoxicity Gentamicin API variants in September 2025, capturing 15% more EU neonatal tenders amid stewardship pushes.

Sandoz B2B expanded U.S. filings for combo Gentamicin API in January 2026, eyeing 20% market lift from sepsis bundle approvals.

Fukang Pharmaceutical faced a brief sterility recall in October 2025 but rebounded with certified batches, retaining 90% China share.

These moves signal a maturing Gentamicin API market, with capacity rationalization and tech infusions set to reshape shares by 2027.

“Gentamicin API Production Data and Gentamicin API Production Trend, Gentamicin API Production Database and forecast”

• • • Gentamicin API production database for historical years, 12 years historical data
    • Gentamicin API production data and forecast for next 8 years